RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Chongqing Lummy Pharmaceutical Co Stock

Chongqing Lummy Pharmaceutical Co ROA 2024

Chongqing Lummy Pharmaceutical Co ROA

-0

Ticker

300006.SZ

ISIN

CNE100000H10

In 2024, Chongqing Lummy Pharmaceutical Co's return on assets (ROA) was -0, a -86.27% increase from the -0.02 ROA in the previous year.

Chongqing Lummy Pharmaceutical Co Aktienanalyse

What does Chongqing Lummy Pharmaceutical Co do?

Chongqing Lummy Pharmaceutical Co Ltd is a leading company in the pharmaceutical products sector. The company was founded in 2001 and is headquartered in Chongqing, China. Its business model focuses on the manufacturing and distribution of pharmaceutical products and medications, including those for the treatment of severe and chronic diseases. Since its establishment, the company has undergone significant development. Through the establishment of research and development departments, the company has been able to develop and manufacture innovative products. This has enabled the company to establish itself as an important player in the market. Chongqing Lummy Pharmaceutical's main products include medications for the treatment of diabetes, cancer, cardiovascular diseases, and mental disorders. The divisions of Chongqing Lummy Pharmaceutical cover various areas of pharmaceutical manufacturing, including the production of tablets, capsules, injection fluids, and ointments. There is also a department specializing in the production of raw materials and active ingredients. This allows Chongqing Lummy Pharmaceutical to control its own value chain and ensure the quality of its products. The company's most well-known products include the insulin injection fluids "Liupanshui," which have been very successful in the Chinese market. The medications "Qiliqiang" and "Jiaonang" for the treatment of breast cancer and the severe acute respiratory syndrome SARS-CoV-2 have also been very successful. The company also has a strong presence in other Asian countries, such as India and Vietnam. Chongqing Lummy Pharmaceutical focuses on quality and innovation. The company holds several certifications and has established a quality assurance system to ensure that all products meet the highest standards. Additionally, the company invests heavily in research and development to bring innovative products to the market. Chongqing Lummy Pharmaceutical also participates in research projects with other companies and institutions to promote collaboration in the pharmaceutical industry. In recent years, the company has achieved strong growth. It has a wide portfolio of products and a strong presence in Asia. In the future, the company plans to further expand its market position and broaden its product range. Chongqing Lummy Pharmaceutical has good chances of establishing itself as a major player in the global market for pharmaceutical products. Chongqing Lummy Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Chongqing Lummy Pharmaceutical Co's Return on Assets (ROA)

Chongqing Lummy Pharmaceutical Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Chongqing Lummy Pharmaceutical Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Chongqing Lummy Pharmaceutical Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Chongqing Lummy Pharmaceutical Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Chongqing Lummy Pharmaceutical Co stock

What is the Return on Assets (ROA) of Chongqing Lummy Pharmaceutical Co this year?

The Return on Assets (ROA) of Chongqing Lummy Pharmaceutical Co is -0 undefined this year.

What was the ROA of Chongqing Lummy Pharmaceutical Co compared to the previous year?

The ROA of Chongqing Lummy Pharmaceutical Co has increased by -86.27% compared to the previous year.

What consequences do high ROA have for investors of Chongqing Lummy Pharmaceutical Co?

A high ROA is advantageous for investors of Chongqing Lummy Pharmaceutical Co, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Chongqing Lummy Pharmaceutical Co?

A low ROA can be unfavorable for investors of Chongqing Lummy Pharmaceutical Co as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Chongqing Lummy Pharmaceutical Co affect the company?

An increase in ROA of Chongqing Lummy Pharmaceutical Co can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Chongqing Lummy Pharmaceutical Co impact the company?

A reduction in the ROA of Chongqing Lummy Pharmaceutical Co can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Chongqing Lummy Pharmaceutical Co?

Some factors that can influence the ROA of Chongqing Lummy Pharmaceutical Co include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Chongqing Lummy Pharmaceutical Co important for investors?

The ROA of Chongqing Lummy Pharmaceutical Co is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Chongqing Lummy Pharmaceutical Co take to improve ROA?

To improve ROA, Chongqing Lummy Pharmaceutical Co can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Chongqing Lummy Pharmaceutical Co pay?

Over the past 12 months, Chongqing Lummy Pharmaceutical Co paid a dividend of 0.05 CNY . This corresponds to a dividend yield of about 1.03 %. For the coming 12 months, Chongqing Lummy Pharmaceutical Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Chongqing Lummy Pharmaceutical Co?

The current dividend yield of Chongqing Lummy Pharmaceutical Co is 1.03 %.

When does Chongqing Lummy Pharmaceutical Co pay dividends?

Chongqing Lummy Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of August, September, August, August.

How secure is the dividend of Chongqing Lummy Pharmaceutical Co?

Chongqing Lummy Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Chongqing Lummy Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chongqing Lummy Pharmaceutical Co located?

Chongqing Lummy Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chongqing Lummy Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chongqing Lummy Pharmaceutical Co from 7/3/2020 amounting to 0.05 CNY, you needed to have the stock in your portfolio before the ex-date on 7/3/2020.

When did Chongqing Lummy Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 7/3/2020.

What was the dividend of Chongqing Lummy Pharmaceutical Co in the year 2023?

In the year 2023, Chongqing Lummy Pharmaceutical Co distributed 0 CNY as dividends.

In which currency does Chongqing Lummy Pharmaceutical Co pay out the dividend?

The dividends of Chongqing Lummy Pharmaceutical Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Chongqing Lummy Pharmaceutical Co

Our stock analysis for Chongqing Lummy Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chongqing Lummy Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.